Doç. Dr. Fehmi Hindilerden
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Myeloproliferative Disorders 6 publicationsSource: OpenAlex / PubMed MeSHView publications
- Thrombosis 5 publications
- Thrombocythemia, Essential 4 publications
- Purpura, Thrombocytopenic, Idiopathic 3 publications
- COVID-19 3 publications
- Bacteremia 2 publications
- Leukemia, Lymphocytic, Chronic, B-Cell 2 publications
- Antiphospholipid Syndrome 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- InstitutionBakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
- Area of workMyeloproliferative DisordersExtracted from 6 publications · Model version —From source
- Publications94 publicationsOpenAlex, Europe PMC, ORCIDFrom source
- ORCID0000-0002-6297-9555ORCIDFrom source
- Last synchronised5 November 2026 08:55https://bakirkoysadikonukeah.saglik.gov.tr/TR-1482136/doktorlarimiz.html#fehmi-hindilerdensaglik.gov.tr
Scientific work
Publications on Myeloproliferative Disorders
-
Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study
Journal of Thrombosis and Thrombolysis, 2026
DOI 10.1007/s11239-026-03363-8 PMID 42565930 Open-access full textSource: OpenAlex
-
Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients
TURKISH JOURNAL OF MEDICAL SCIENCES, 2026
DOI 10.55730/1300-0144.6184 PMID 42058976 Open-access full textSource: OpenAlex
-
Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study
Journal of clinical medicine, 2026
DOI 10.3390/jcm15020854 PMID 41598791 1 citation (Europe PMC) Open-access full textSource: Europe PMC
-
(PB2953) REAL-WORLD EFFICACY AND CARDIOVASCULAR SAFETY OF ACALABRUTINIB IN B-CELL MALIGNANCIES: A TURKISH MULTICENTER EXPERIENCE COMPARING FRONTLINE INITIATION VS. TRANSITION AFTER IBRUTINIB INTOLERANCE Topic: 06. Chronic lymphocytic leukemia and related disorders -Clinical
2026
DOI 10.13140/rg.2.2.20277.44000 Source: OpenAlex
-
Evaluation of bloodstream infections in febrile neutropenic patients with hematological malignancy: a retrospective cohort study
BMC Infectious Diseases, 2026
DOI 10.1186/s12879-026-13465-6 PMID 42056949 2 citations (Europe PMC) Open-access full textSource: ORCID
-
CLINICAL IMPACT OF ELTROMBOPAG-ASSOCIATED IRON CHELATION IN ADULTS WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER REAL-WORLD STUDY
Mediterranean Journal of Hematology and Infectious Diseases, 2026
DOI 10.4084/mjhid.2026.027 PMID 41821563 Open-access full textSource: ORCID
-
Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia
Hemato, 2026
DOI 10.3390/hemato7020016 Open-access full textSource: ORCID
-
A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond
Blood advances, 2026
DOI 10.1182/bloodadvances.2025017896 PMID 41092481 2 citations (Europe PMC) Open-access full textSource: Europe PMC
-
Emerging Survival Predictor Model in Essential Thrombocythemia: The AAA + Model
American Journal of Hematology, 2026
DOI 10.1002/ajh.70254 PMID 41793248 Open-access full textSource: OpenAlex
-
MİYELOPROLİFERATİF NEOPLAZMLARDA SPLANKNİK VEN TROMBOZUNUN DEĞERLENDİRİLMESİ: THD KRONİK MİYELOSİTER LÖSEMİ VE KRONİK MİYELOPROLİFERATİF NEOPLAZMLAR VE HEMOSTAZ - TROMBOZ BİLİMSEL ALT KOMİTELERİ ÇOK MERKEZ ÇALIŞMASI
Bursa Uludag University - AVESIS, 2025
Source: OpenAlex